The Injurious Effects of Hyperinsulinism on Blood Vessels

Cell Biochemistry and Biophysics

Volumn 69, Issue 2, 2014, Pages 213-218

  Wang, Xukai ^a   Yu, Changqing ^a   Zhang, Bo ^a   Wang, Yan ^a  

^a CHONGQING MEDICAL UNIVERSITY   (China)

Author keywords

Atherosclerosis; Hyperinsulinemia; Insulin resistance

Indexed keywords

MITOGEN ACTIVATED PROTEIN KINASE KINASE; NITRIC OXIDE; SOMATOMEDIN C RECEPTOR;

ARTERIOSCLEROSIS; COMPLICATION; DRUG EFFECTS; HUMAN; HYPERINSULINISM; HYPERTENSION; INSULIN RESISTANCE; METABOLISM; PATHOLOGY; SMOOTH MUSCLE FIBER; TOXICITY; VASCULAR ENDOTHELIUM;

ARTERIOSCLEROSIS; ENDOTHELIUM, VASCULAR; HUMANS; HYPERINSULINISM; HYPERTENSION; INSULIN RESISTANCE; MITOGEN-ACTIVATED PROTEIN KINASE KINASES; MYOCYTES, SMOOTH MUSCLE; NITRIC OXIDE; RECEPTOR, IGF TYPE 1;

EID: 84901241568     PISSN: 10859195     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12013-013-9810-6     Document Type: Review

References (39)

1. Reaven, G. M. (1995). Pathophysiology of insulin resistance in human disease. Physiological Reviews, 75, 473-476.
2. Zheng, H., Worrall, C., Shen, H., Issad, T., Seregard, S., Girnita, A., et al. (2012). Selective recruitment of G protein-coupled receptor kinases (GRKs) controls signaling of the insulin-like growth factor 1 receptor. Proceedings of the National Academy of Sciences United States of America, 109, 7055-7060.
3. Ganugapati, J., Baldwa, A., & Lalani, S. (2012). Molecular docking studies of banana flower flavonoids as insulin receptor tyrosine kinase activators as a cure for diabetes mellitus. Bioinformation, 8, 216-220.
4. De Rocca Serra-Nédélec, A., Edouard, T., Tréguer, K., Tajan, M., Araki, T., Dance, M., et al. (2012). Noonan syndrome-causing SHP2 mutants inhibit insulin-like growth factor 1 release via growth hormone-induced ERK hyperactivation, which contributes to short stature. Proceedings of the National Academy of Sciences United States of America, 109, 4257-4262.
5. Caccamo, G., Bonura, F., Bonura, F., Vitale, G., Novo, G., Evola, S., et al. (2010). Insulin resistance and acute coronary syndrome. Atherosclerosis, 211, 672-675.
6. Siddals, K. W., Allen, J., Sinha, S., Canfield, A. E., Kalra, P. A., & Gibson, J. M. (2011). Apposite insulin-like growth factor (IGF) receptor glycosylation is critical to the maintenance of vascular smooth muscle phenotype in the presence of factors promoting osteogenic differentiation and mineralization. Journal of Biological Chemistry, 286, 16623-16630.
7. Kim, J. A., Montagnani, M., Koh, K. K., et al. (2006). Reciprocal relationships between insulin resistance and endothelial dysfunction: molecular and pathophysiological mechanisms. Circulation, 113, 1888-1904.
8. Negri, M., Sheiban, I., Arigliano, P. L., Tonni, S., Montresor, G., Carlini, S., et al. (1993). Interrelation between angiographic severity of coronary artery disease and plasma levels of insulin, C peptide and plasminogen activator inhibitor-1. American Journal of Cardiology, 72, 397-401.
9. Hill, M. M., Connolly, L. M., Simpson, R. J., & James, D. E. (2000). Differential protein phosphorylation in 3T3-L1 adipocytes in response to insulin versus platelet-derived growth factor. No evidence for a phosphatidylinositide 3-kinase-independent pathway in insulin signaling. Journal of Biological Chemistry, 275, 24313-24320.
10. Solymss, B. C., Marcil, M., Chaour, M., et al. (1995). Fasting hyperinsulinism, insulin resistance syndrome, and coronary artery disease in men and women. American Journal of Cardiology, 76, 1152-1156.
11. Tsuchihashi, K., HikitaN, Hase M, et al. (1999). Role of hyperinsulinemia in atherosclerotic coronary arterial disease: studies of semi quantitative coronary angiography. Internal Medicine, 38, 691-697.
12. Lee, K. K., Cipriano, L. E., Owens, D. K., Go, A. S., & Hlatky, M. A. (2010). Cost-effectiveness of using high-sensitivity C-reactive protein to identify intermediate- and low-cardiovascular-risk individuals for statin therapy. Circulation, 122, 1478-1487.
13. Solymoss, B. C., Bourassa, M. G., Campeau, L., Sniderman, A., Marcil, M., Lespérance, J., et al. (2004). Effect of increasing metabolic syndrome score on atherosclerotic risk profile and coronary artery disease angiographic severity. American Journal of Cardiology, 93, 159-164.
14. Lee, K. K., Fortmann, S. P., Fair, J. M., Iribarren, C., Rubin, G. D., Varady, A., et al. (2009). Insulin resistance independently predicts the progression of coronary artery calcification. American Heart Journal, 157, 939-945.
15. Eringa, E. C., Stehouwer, C. D., Merlijn, T., Westerhof, N., & Sipkema, P. (2002). Physiological concentrations of insulin induce endothelin-mediated vasoconstriction during inhibition of NOS or PI3-kinase in skeletal muscle arterioles. Cardiovascular Research, 56, 464-471.
16. Taguchi, K., Matsumoto, T., Kamata, K., & Kobayashi, T. (2012). G protein-coupled receptor kinase 2, with β-arrestin 2, impairs insulin-induced Akt/endothelial nitric oxide synthase signaling in ob/ob mouse aorta. Diabetes, 61, 1978-1985.
17. Zhang, W., Wang, X., Jin, H., Qian, R., Zhang, G., Chen, S., et al. (2008). Effects of high glucose plus high [2] insulin on proliferation and apoptosis of mouse endothelial progenitor cells. Inflammation Research, 57, 571-576.
18. Zhao, L., Cao, F., Yin, T., Sun, D., Cheng, K., Zhang, J., et al. (2011). Moderate dose insulin promotes function of endothelial progenitor cells. Cell Biology International, 35, 215-220.
19. Wang, Y., Cheng, K. K., Lam, K. S., Wu, D., Wang, Y., Huang, Y., et al. (2011). APPL1 counteracts obesity-induced vascular insulin resistance and endothelial dysfunction by modulating the endothelial production of nitric oxide and endothelin-1 in mice. Diabetes, 60, 3044-3054.
20. Liu, K., Zhao, W., Gao, X., Huang, F., Kou, J., & Liu, B. (2012). Diosgenin ameliorates palmitate-induced endothelial dysfunction and insulin resistance via blocking IKKβ and IRS-1 pathways. Atherosclerosis, 223, 350-358.
21. Takebayashi, K., Sohma, R., Aso, Y., & Inukai, T. (2011). Effects of retinol binding protein-4 on vascular endothelial cells. Biochemical and Biophysical Research Communications, 408, 58-64.
22. Sobrevia, L., Nadal, A., Yudilevich, D. L., & Mann, G. E. (1996). Activation of l-arginine transport (system y +) and nitric oxide synthase by elevated glucose and insulin in human endothelial cells. Journal of Physiology, 490, 775-781.
23. Bollig-Fischer, A., Dewey, T. G., & Ethier, S. P. (2011). Oncogene activation induces metabolic transformation resulting in insulin-independence in human breast cancer cells. PLoS One, 6, e17959.
24. Bouallegue, A., Vardatsikos, G., & Srivastava, A. K. (2010). Involvement of insulin-like growth factor 1 receptor transactivation in endothelin-1-induced signaling in vascular smooth muscle cells. Canadian Journal of Physiology and Pharmacology, 88, 501-509.
25. Xu, Q., Li, S., Zhao, Y., Maures, T. J., Yin, P., & Duan, C. (2004). Evidence that IGF binding protein-5 functions as a ligand-independent transcriptional regulator in vascular smooth muscle cells. Circulation Research, 94, E46-E54.
26. Kihara, M., Robinson, P. J., Buck, S. H., & Dage, R. C. (1989). Mitogenesis by serum and PDGF is independent of PI degradation and PKC in VSMC. American Journal of Physiology, 256, C886-C892.
27. Kiess, W., Kratzsch, J., Kruis, T., Müller, E., Wallborn, T., Odeh, R., et al. (2011). Genetics of human stature: Insight from single gene disorders. Hormone Research in Paediatrics, 76(Suppl 3), 11-13.
28. Mohamadi, A., Clark, L. M., Lipkin, P. H., Mahone, E. M., Wodka, E. L., & Plotnick, L. P. (2010). Medical and developmental impact of transition from subcutaneous insulin to oral glyburide in a 15-year-old boy with neonatal diabetes mellitus and intermediate DEND syndrome: extending the age of KCNJ11 mutation testing in neonatal DM. Pediatric Diabetes, 11, 203-207.
29. Oçal, G., Flanagan, S. E., Hacihamdioǧlu, B., Berberoǧlu, M., Siklar, Z., Ellard, S., et al. (2011). Clinical characteristics of recessive and dominant congenital hyperinsulinism due to mutation(s) in the ABCC8/KCNJ11 genes encoding the ATP-sensitive potasium channel in the pancreatic beta cell. Journal of Pediatric Endocrinology and Metabolism, 24, 1019-1023.
30. Zhang, W., Shen, X., Wan, C., Zhao, Q., Zhang, L., Zhou, Q., et al. (2012). Effects of insulin and insulin-like growth factor 1 on osteoblast proliferation and differentiation: differential signalling via Akt and ERK. Cell Biochemistry and Function, 30(4), 297-302. doi: 10. 1002/cbf. 2801.
31. Liu, C. H., & Wu, K. W. (2009). Synergistic effects of basic fibroblast growth factor and insulin on Chinese hamster ovary cells under serum-free conditions. Journal of Bioscience and Bioengineering, 107, 312-317.
32. Hickman, J., & McElduff, A. (1989). Insulin promotes growth of the cultured rat osteosarcoma cell line UMR-106-01: an osteoblast-like cell. Endocrinology, 124, 701-706.
33. Vishwamitra, D., Shi, P., Wilson, D., Manshouri, R., Vega, F., Schlette, E. J., et al. (2011). Expression and effects of inhibition of type I insulin-like growth factor receptor tyrosine kinase in mantle cell lymphoma. Haematologica, 96, 871-880.
34. Yamazaki, M., Sato, A., Nishio, S., Takeda, T., Miyamoto, T., Katai, M., et al. (2009). Acromegaly accompanied by Turner syndrome with 47, XXX/45, X/46, XX mosaicism. Internal Medicine, 48, 447-453.
35. Lim, S., Park, Y. M., Sakuma, I., & Koh, K. K. (2012). How to control residual cardiovascular risk despite statin treatment: Focusing on HDL-cholesterol. International Journal of Cardiology, 166(1), 8-14.
36. Robins, S. J., Lyass, A., Zachariah, J. P., Massaro, J. M., & Vasan, R. S. (2011). Insulin resistance and the relationship of a dyslipidemia to coronary heart disease: the Framingham Heart Study. Arteriosclerosis, Thrombosis, and Vascular Biology, 31, 1208-1214.
37. Mouquet, F., Cuilleret, F., Susen, S., Sautière, K., Marboeuf, P., Ennezat, P. V., et al. (2009). Metabolic syndrome and collateral vessel formation in patients with documented occluded coronary arteries: association with hyperglycaemia, insulin-resistance, adiponectin and plasminogen activator inhibitor-1. European Heart Journal, 30, 840-849.
38. Pandolfi, A., Cetrullo, D., Polishuck, R., Alberta, M. M., Calafiore, A., Pellegrini, G., et al. (2001). Plasminogen activator inhibitor type 1 is increased in the arterial wall of type II diabetic subjects. Arteriosclerosis, Thrombosis, and Vascular Biology, 21, 1378-1382.
39. von der Thüsen, J. H., Borensztajn, K. S., Moimas, S., van Heiningen, S., Teeling, P., van Berkel, T. J., et al. (2011). IGF-1 has plaque-stabilizing effects in atherosclerosis by altering vascular smooth muscle cell phenotype. American Journal of Pathology, 178, 924-934.